Biodistribution and Safety Assessment of Bladder Cancer Specific Recombinant Oncolytic Adenovirus in Subcutaneous Xenografts Tumor Model in Nude Mice

Author(s): Fang Wang, Zhiping Wang, Hongwei Tian, Meijiao Qi, Zhenxing Zhai, Shuwen Li, Renju Li, Hongjuan Zhang, Wenyun Wang, Shenjun Fu, Jianzhong Lu, Ronald Rodriguez, Yinglu Guo, Liqun Zhou.

Journal Name: Current Gene Therapy

Volume 12 , Issue 2 , 2012

Become EABM
Become Reviewer


Background: The previous works about safety evaluation for constructed bladder tissue specific adenovirus are poorly documented. Thus, we investigated the biodistribution and body toxicity of bladder specific oncolytic adenovirus Ad-PSCAE-UPII-E1A (APU-E1A) and Ad-PSCAE-UPII-E1A-AR (APU-E1A-AR), providing meaningful information prior to embarking on human clinical trials. Materials and Method: Conditionally replicate recombinant adenovirus (CRADs) APU-E1A, APU-EIA-AR were constructed with bladder tissue specific UroplakinII(UPII) promoter to induce the expression of Ad5E1A gene and E1A-AR fusing gene, and PSCAE was inserted at upstream of promoter to enhance the function of promoter. Based on the cytopathic and anti-tumor effect of bladder cancer, these CRADs were intratumorally injected into subcutaneous xenografts tumor in nude mice. We then determined the toxicity through general health and behavioral assessment, hepatic and hematological toxicity evaluation, macroscopic and microscopic postmortem analyses. The spread of the transgene E1A of adenovirus was detected with RT-PCR and Western blot. Virus replication and distribution were examined with APU-LUC administration and Luciferase Assay. Results: General assessment and body weight of the animals did not reveal any alteration in general behavior. The hematological alterations of groups which were injected with 5x108 pfu or higher dose (5x109 pfu) of APU-E1A and APU-E1A-AR showed no difference in comparison with PBS group, and only slight increased transaminases in contrast to PBS group at 5x109 pfu of APU-E1A and APU-E1A-AR were observed. E1A transgene did not disseminate to organs outside of xenograft tumor. Virus replication was not detected in other organs beside tumor according to Luciferase Assay. Conclusions: Our study showed that recombinant adenovirus APU-E1A-AR and APU-E1A appear safe with 5x107 pfu and 5x108 pfu intratumorally injection in mice, without any discernable effects on general health and behavior.

Keywords: Bladder cancer, gene therapy, oncolytic adenovirus, biodistribution, safety assessment

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Page: [67 - 76]
Pages: 10
DOI: 10.2174/156652312800099599
Price: $65

Article Metrics

PDF: 10